Skip to main content

Targeting IRE1 in disease

Objetivo

The overarching objective of this Interfere to Suppress or Promote IRE1 (INSPIRED) RISE programme is to drive research and innovation in cell stress and drug development for cancer and neurodegenerative diseases by forming an interdisciplinary and intersectoral network of experts with strong, dynamic and productive interactions. The partners will work together, each bringing their unique expertise, to develop new classes of therapeutics for these common diseases. By fostering a shared culture of research, innovation and collaboration, the participants will accelerate advances in the field of cell stress responses. The staff members who participate in the programme will develop new skills, learn new technologies and be exposed to new environments which will considerably enhance their career opportunities. Advancing drug development in the stress response field has potential translational and commercial opportunities for the participants and will benefit European society as a whole from economic and health perspectives.
IRE1 is a stress sensor and signal transducer, activated in response to the accumulation of misfolded proteins in the endoplasmic reticulum (ER). Its activation is part of a process termed the unfolded protein response (UPR) that determines the fate of cells in response to ER stress. The INSPIRED consortium will focus on understanding IRE1 signalling and its role in the stress response in order to target it in specific diseases such as cancers and neurodegenerative disorders where aberrant IRE1 signalling occurs. Research carried out by INSPIRED partners will develop new IRE1 modulators and generate preclinical data to support targeting IRE1 in cancers and neurodegenerative disease.

Convocatoria de propuestas

H2020-MSCA-RISE-2016
Consulte otros proyectos de esta convocatoria

Coordinador

NATIONAL UNIVERSITY OF IRELAND GALWAY
Dirección
University Road
H91 Galway
Irlanda
Tipo de actividad
Higher or Secondary Education Establishments
Aportación de la UE
€ 342 000

Participantes (5)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Francia
Aportación de la UE
€ 135 000
Dirección
Rue De Tolbiac 101
75654 Paris
Tipo de actividad
Research Organisations
ENIOS APPLICATIONS IDIOTIKI KEFALAIOUCHIKI ETAIREIA
Greece
Aportación de la UE
€ 162 000
Dirección
Al. Pantou 25
17671 Kallithea
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
METASYSX GMBH
Alemania
Aportación de la UE
€ 9 000
Dirección
Am Mühlenberg 11
14476 Potsdam
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GOETEBORGS UNIVERSITET
Suecia
Aportación de la UE
€ 27 000
Dirección
Vasaparken
405 30 Goeteborg
Tipo de actividad
Higher or Secondary Education Establishments
CELL STRESS DISCOVERIES LIMITED
Irlanda
Aportación de la UE
€ 157 500
Dirección
Unit 204, Nuig Business Innovation Centre, Newcastle Road
Galway
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Socios (3)

UNIVERSIDAD DE CHILE
Chile
Dirección
Av. Libertador Bernardo O'higgins 1058
10 Santiago
Tipo de actividad
Higher or Secondary Education Establishments
MANNKIND CORPORATION

La participación finalizó

Estados Unidos
Dirección
North Avenue Paine 28903
91355 Valencia
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ORINOVE INC
Estados Unidos
Dirección
3537 Old Conejo Road Suite 104
91320 Newbury Park
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)